mbxbio.comHealthcare / BioTech & PharmaFounded: 2019Funding to Date: $216.64MM
MBX Biosciences is a clinical-stage biopharmaceutical company that specializes in developing therapies to treat rare endocrine diseases and metabolic disorders.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
08/05/2024 | Series C | $63.5MM | $xx.xx | $316.71MM | Deep Track Capital, Driehaus Capital Management, T. Rowe Price Associates, Frazier Life Sciences, OrbiMed, Wellington Management | |
Price per Share
$xx.xx
Shares Outstanding
61,650,480
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Deep Track Capital, Driehaus Capital Management, T. Rowe Price Associates, Frazier Life Sciences, OrbiMed, Wellington Management
|
||||||
11/14/2022 | Series B | $116.32MM | $xx.xx | $235.08MM | Wellington Management, RA Capital Management, Norwest Venture Partners, Frazier Life Sciences, NEA, OrbiMed | |
Price per Share
$xx.xx
Shares Outstanding
129,240,032
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Wellington Management, RA Capital Management, Norwest Venture Partners, Frazier Life Sciences, NEA, OrbiMed
|
||||||
07/27/2020 | Series A | $36.82MM | $xx.xx | $61.37MM | Frazier Healthcare Partners, OrbiMed, NEA, BioCrossroads, Twilight Venture Partners, IU Ventures | |
Price per Share
$xx.xx
Shares Outstanding
53,598,587
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Frazier Healthcare Partners, OrbiMed, NEA, BioCrossroads, Twilight Venture Partners, IU Ventures
|